
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc has demonstrated significant financial growth, with total revenue increasing by 84.7% year-over-year, largely driven by a remarkable 117.2% rise in genomics revenue to $252.9 million. The company's laboratory test offerings, including the xF liquid biopsy assay and xT CDx test, are expected to see higher average selling prices, bolstered by expected additional pharma contracts and improved reimbursements for its MRD products. Furthermore, oncology testing volume increased by 27%, indicating a robust demand for Tempus' Intelligent Diagnostics solutions, which utilize AI technology to enhance the accuracy and personalization of laboratory testing.
Bears say
Tempus AI Inc. experienced a significant decline in gross margins from 76.8% to 69.7% in its Data & Other segment, which raises concerns about its ability to maintain profitability amidst increasing operational costs and potential market challenges. The company has also incurred substantial losses since its inception and carries a considerable debt load of $518.8 million, suggesting ongoing financial strain and a risk of sustained losses in the future. Additionally, operating cash flow decreased by $168.5 million year-over-year, indicating potential liquidity issues that may hinder investments in growth and innovation, further complicating its path to achieving sustainable profitability.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares